Key result
Nisoldipine co-administration significantly elevated mean digoxin trough plasma concentrations from 1.16 to 1.35 ng/ml and shortened the pre-ejection period in patients with heart failure.
Why the study?
Does nisoldipine co-administration alter digoxin plasma levels and haemodynamic effects in patients with heart failure?
Population
10 patients with heart failure
Comparison
Nisoldipine co-administered with digoxin vs Placebo co-administered with digoxin
Design
RCT, double-blind
Authors
Loading...
Monitor digoxin levels with nisoldipine in heart failure; extends RCT evidence of a clinically relevant pharmacokinetic interaction with hemodynamic effects.
RCT (n=10)
Double-blind
Randomized
No
Does nisoldipine co-administration alter digoxin plasma levels and haemodynamic effects in patients with heart failure?
Absolute Event Rate: 1.35% vs 1.16%
p-value: p=<0.05
Nisoldipine co-administration significantly increases digoxin plasma concentrations in heart failure patients, highlighting a potentially clinically relevant drug interaction.
Kirch et al. (1986) conducted an RCT in Cardiac insufficiency (NYHA stage II-III) (n=10). Nisoldipine vs. Placebo was evaluated on Mean digoxin trough plasma concentration (days 5, 6, and 7) (p=<0.05). Nisoldipine co-administration significantly elevated mean digoxin trough plasma concentrations from 1.16 to 1.35 ng/ml and shortened the pre-ejection period in patients with heart failure.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: